No Data
CORRECTION: Bioage Labs Ticker Is "BIOA"
BioAge Labs To Present New Preclinical Data For Lead Product Candidate Azelapragor At ObesityWeek 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Bio-Rad Laboratories Shares Are Trading Higher After Citigroup Maintained a Buy Rating on the Stock and Raised Its Price Target From $400 to $450.
Express News | NYSE Halt Bio-Rad Labs B Add Info Lst $334.850000
A Quick Look at Today's Ratings for Bio-Rad Laboratories(BIO.US), With a Forecast Between $360 to $469
No Data
No Data